Skip to product information
1 of 1

NSJ Bioreagents

SKU:V9378-100UG

IDH1 Antibody / Isocitrate Dehydrogenase (R132H mutant), 100 ug

IDH1 Antibody / Isocitrate Dehydrogenase (R132H mutant), 100 ug

Regular price $559.00 USD
Regular price Sale price $559.00 USD
Sale Sold out
Shipping calculated at checkout.
Size

IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.

Specifications

Catalog No V9378-100UG
Family Primary antibody
Qty 100 ug
Formulation 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
Format Purified
Clone IDH1/6806R
Host Animal Rabbit
Clonality Recombinant Rabbit Monoclonal
Isotype Rabbit IgG, kappa
Species Reactivity Human
Application IHC-P
Application Details Immunohistochemistry (FFPE): 1-2ug/ml
Application Note Optimal dilution of the IDH1 R132H antibody should be determined by the researcher.
Localization Cytoplasm, Nucleus
Immunogen A portion of amino acids 281-414 was used as the immunogen for the IDH1 R132H antibody.
Purity Protein A/G affinity
Storage Aliquot the IDH1 R132H antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Limitation This IDH1 R132H antibody is available for research use only.
Uniprot # O75874
Status Available
PDF Link https://www.nsjbio.com/tds-pdf/idh1-antibody-isocitrate-dehydrogenase-r132h-mutant-idh16806r-v9378
Title IDH1 Antibody / Isocitrate Dehydrogenase (R132H mutant)
Description IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.
View full details